The invention provides kinase inhibitor compounds of the formula (1): or salts, solvates, tautomers or N-oxides thereof wherein X is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2 m is 0-2 n is 0-1 q is 0-2 A is C1-6 alkylene optionally interrupted by O R1 is halogen, cyano, nitro, an optionally substituted acyclic C1-6 hydrocarbon group, optionally substituted C3-7 cycloalkyl, optionally substituted phenyl, optionally substituted five membered heteroaryl, NR2R3, Ra-Rb, O-Rb or C(O)NR2R8 R4 is fluorine, chlorine, methyl or cyano R2 is hydrogen or optionally substituted C1-4 alkyl R3 is Ra-Rb or NR2R3 forms a 4 to 7 membered non-aromatic heterocyclic ring Ra is a bond, C(X2), C(X2)X1, SO, SO2 or SO2NRc Rb is hydrogen or an optionally substituted 3 to 7-membered carbocyclic or heterocyclic ring or an optionally substituted C1-12 acyclic hydrocarbon group Rc is hydrogen or a C1-4 hydrocarbon group Rd is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2 X1 is O, S or NRc X2 is =O, =S or =NRc but excluding the compound wherein m, n and q are all 0, A is CH2 and NR2R3 is a 2-phenylmorpholin-4-yl group.
